ESLA
Estrella Immunopharma Inc (ESLA)
Healthcare • NASDAQ • $0.98-2.00%
- Symbol
- ESLA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.98
- Daily Change
- -2.00%
- Market Cap
- $40.88M
- Trailing P/E
- N/A
- Forward P/E
- -2.97
- 52W High
- $3.15
- 52W Low
- $0.78
- Analyst Target
- $12.00
- Dividend Yield
- N/A
- Beta
- 0.85
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candid…
Company websiteResearch ESLA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.